• Add description, images, menus and links to your mega menu

  • A column with no settings can be used as a spacer

  • Link to your collections, sales and even external links

  • Add up to five columns

  • février 25, 2026 2 lire la lecture

    Maternal infection is a significant cause of maternal illness and death worldwide. It is
    associated with as many as half of in-hospital maternal deaths, with the greatest burden
    observed in low- and middle-income countries where early detection and treatment remain challenging. Outcomes are especially poor in cases involving maternal sepsis. A landmark trial, the APT-Sepsis trial, published in the New England Journal of Medicine shows that a practical, low-cost intervention can dramatically reduce these preventable deaths.

    What is FAST-M?

    FAST-M is a maternal sepsis care bundle designed specifically for resource-limited settings. The acronym guides healthcare providers through five critical steps:

    • Fluids
    • Antibiotics
    • Source control
    • Transfer (if needed)
    • Monitoring of mother and baby

    The APT-Sepsis Trial Results

    The Active Prevention and Treatment of Maternal Sepsis (APT-Sepsis) trial scaled up this
    approach across 59 hospitals in Malawi and Uganda, with 30 assigned to the intervention group (15 in Malawi and 15 in Uganda) and 29 to the usual-care group (15 and 14, respectively), involving 431,394 women. The intervention combined three goals:

    1. to improve hand-hygiene adherence,
    2. to improve the prevention and management of maternal infection, and
    3. to increase early recognition and bundled treatment of sepsis (FAST-M)

    Key findings:

    • Implementation of the APT-Sepsis program led to a significantly lower risk of a
      composite outcome of infection-related maternal death, infection-related near-miss event, or severe infection-related illness than usual care.
    • For each of the goals the intervention of the APT-Sepsis program:

    o Increased hand hygiene compliance by 14%
    o Improved prevention in management of maternal infection via appropriate
    antibiotic prophylaxis use by 15%
    o Increased early recognition (32%) and bundled treatment of sepsis (8%)

    • Effectiveness increased over time, with increased success by the final month of the trial.
    • Results were consistent across both countries.
    • No costly new resources required.


    Why It Works in Low-Resource Settings

    Unlike many maternal health interventions, APT-Sepsis was designed from the ground up for feasibility in resource-constrained environments. The program:

    • Embeds within existing health systems
    • Uses readily available medications and supplies
    • Provides clear decision-making tools for frontline staff
    • Requires minimal additional training

    The intervention leverages modified early warning scores to track vital signs and trigger the FAST-M protocol when sepsis is suspected—a systematic approach that replaces inconsistent practices with standardized care.

    Looking Ahead

    These results demonstrate that structured, system-level interventions can overcome
    longstanding barriers in maternal sepsis care. The low-cost, sustainable model is
    designed for rapid scale-up through national and international health programs.
    Extending this intervention to other countries and settings may require partnering with
    national ministries of health, as in this trial, to facilitate uptake of the intervention and
    to adapt materials and processes to ensure they are culturally and contextually
    appropriate.

    Further work is needed to evaluate patient and provider experiences, behavior changes,
    and the cost-effectiveness of the intervention.

    Read the full study:

    "A Multicomponent Intervention to Improve Maternal Infection Outcomes"
    in the New England Journal of Medicine (2025)

     By Brittany de Soto Palmer

    Laisser un commentaire

    Les commentaires sont approuvés avant leur publication.


    Voir l'article entier

    The High Quality Maternova Non-pneumatic anti-shock garment (NASG)
    The High Quality Maternova Non-pneumatic anti-shock garment (NASG)

    mai 25, 2026 1 lire la lecture

    High quality ISO 13485 and CE-marked Non-pneumatic anti shock garments (NASG) produced by Maternova for use by midwives and obstetricians all over the world to save lives threatened by postpartum hemorrhage.  Our NASGS adhere to the highest standards and are trusted by hundreds of clinicians. 

    Voir l'article entier
    A $.03 pill that could prevent maternal deaths; Part 4
    A $.03 pill that could prevent maternal deaths; Part 4

    mai 25, 2026 2 lire la lecture

    The USPSTF, ACOG, the Society for Maternal-Fetal Medicine, and FIGO all recommend low dose aspirin (LDA) for high-risk pregnancies. The barriers are systemic, behavioral, and structural.

    Voir l'article entier
    A $.03 pill that could save maternal lives: low dose aspirin.... Part 3
    A $.03 pill that could save maternal lives: low dose aspirin.... Part 3

    mai 25, 2026 2 lire la lecture

    A 2025 study at a Federally Qualified Health Center (FQHC) serving a socially vulnerable population proved that with implementation of a universal low dose aspirin protocol, adherence jumped from 8.7% to 75%.

    Voir l'article entier